DGAP-News

Epigenomics AG: Epigenomics to present at the Oppenheimer 25th Annual Healthcare Conference

DGAP-News: Epigenomics AG / Key word(s): Conference
Epigenomics AG: Epigenomics to present at the Oppenheimer 25th Annual
Healthcare Conference

10.12.2014 / 09:30

---------------------------------------------------------------------

Epigenomics to present at the Oppenheimer 25th Annual Healthcare Conference

Berlin (Germany) and Germantown, MD (U.S.A.), December 10, 2014 -
Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the
German-American cancer molecular diagnostics company, today announced that
CEO/CFO Dr. Thomas Taapken will be presenting at the Oppenheimer 25th
Annual Healthcare Conference on Wednesday, December 10, 2014, at 9.45 a.m.
EST in room ACT IV of The Crowne Plaza Hotel in New York City, USA.

The Oppenheimer 25th Annual Healthcare Conference will take place on
December 10-11, 2014 and is one of the most important international
investor conferences introducing a broad spectrum of public and private
healthcare companies spanning all major sectors of the healthcare industry.

The presentation will be available on Epigenomics' website:
http://www.epigenomics.com/en/news-investors.html.

- Ends -

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Geneststraße 5
10829 Berlin
Tel [phone]
[e-mail]
www.epigenomics.com

For US press inquiries:

Epigenomics, Inc.
20271 Goldenrod Lane, Suite 2027
Germantown, Maryland 20876
[e-mail]

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in
Europe, has received approval by the Chinese Food and Drug Administration
for China and is under regulatory review by the U.S. Food and Drug
Administration (FDA). Additionally, the Company markets its tissue assay
for use in lung cancer diagnosis, Epi proLung(R), in Europe. The Company's
technology and products have been validated through multiple partnerships
with leading global diagnostic companies and testing laboratories.
Epigenomics is an international company with operations in Europe and the
U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements